MRT‑2359 is an investigational, orally bioavailable molecular‑glue degrader targeting GSPT1, a protein involved in translation termination. We talked about this new molecule in this article just one month ago, we already have some good news. In prostate cancer it is being studied in combination with androgen‑receptor (AR)‑axis inhibitors, particularly in metastatic castration‑resistant prostate cancer (mCRPC), […]
A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]
A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]
A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]
Hormone therapy has been a cornerstone for treating advanced prostate cancer, starving tumors of the male hormones they crave to grow. But it often brings harsh side effects like crushing fatigue, hot flashes, high blood pressure, and loss of muscle mass that make daily life a struggle for many men. Now, a major new UK […]
P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]
The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]
SYS6043 is a new type of antibody-drug conjugate, or ADC. It zeroes in on B7-H3, a protein that is expresse by advanced tumors but almost not at all on healthy cells. The antibody part sticks to B7-H3, gets pulled inside the cancer cell, and releases a topoisomerase I inhibitor that breaks the cell’s DNA and […]
The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]
The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy